Clinical Trial

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (MK3475-587)

Brief Summary: The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study.

Key Eligibility Criteria:

• Treated on the parent pembrolizumab studies established by the Sponsor as MK-3475-587 ready.
• Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinib from parent studies or in a follow-up phase
• Has not received any anticancer systemic treatment since the last dose of pembrolizumab or a pembrolizumab-based combination in First Course Phase.
• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients excluded
• Has a known additional malignancy that is progressing or requires active treatment excluded